Bjerring P, Christiansen K, Troilius A
Department of Dermatology, University Hospital of Aarhus, Aarhus, Denmark.
J Cosmet Laser Ther. 2001 Dec;3(4):169-73. doi: 10.1080/14764170160260744.
The purpose of this clinical study was to evaluate the effectiveness of the first intense pulsed light source (IPL) with dual mode light filtering for treatment of facial telangiectasias, and to evaluate the incidence of adverse including purpura, pigmentation and scars.
Twenty-four patients with facial telangiectasias were treated between one and four times with a new IPL system. This system differs from previous IPLs by eliminating wavelengths longer than 950 nm, which would otherwise lead to non-specific heating of tissue water. The treatments were performed at one-month intervals. Two months after the last treatment, the clinical effect was evaluated from close-up photographs.
After one to four IPL treatments (mean: 2.54; SD: 0.96) for facial telangiectasias, 79.2% of the patients obtained a more than 50% reduction in number of vessels, and 37.5% obtained between a 75% and 100% reduction. Moderate erythema and oedema were the only adverse effects of the treatment. No purpura was registered and no long-term adverse effects such as scars or pigmentary disturbances occurred.
An IPL with dual mode filtering is efficient and safe for treatment of facial telangiectasias.
本临床研究旨在评估首款具有双模式滤光功能的强脉冲光(IPL)治疗面部毛细血管扩张症的有效性,并评估包括紫癜、色素沉着和瘢痕等不良反应的发生率。
24例面部毛细血管扩张症患者接受了新型IPL系统治疗,治疗次数为1至4次。该系统与以往的IPL不同,它消除了波长大于950nm的光,否则会导致组织水分的非特异性加热。治疗间隔为1个月。最后一次治疗后2个月,通过特写照片评估临床效果。
对面部毛细血管扩张症进行1至4次IPL治疗(平均:2.54;标准差:0.96)后,79.2%的患者血管数量减少超过50%,37.5%的患者血管数量减少75%至100%。治疗的唯一不良反应是中度红斑和水肿。未出现紫癜,也未发生瘢痕或色素紊乱等长期不良反应。
具有双模式滤光功能的IPL治疗面部毛细血管扩张症有效且安全。